TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06635018

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resting conditions
Description: The volunteer's hands are at rest and PI readings are taken for six minutes. After two minutes, there is always a randomized rotation of the sensors between the fingers.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Movement artifacts
Description: The volunteer periodically spreads his/her fingers and clenches them into a fist, and PI readings are taken for six minutes. After two minutes there is always a randomized rotation of sensors between the fingers.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Circulation constriction
Description: The volunteer's arm is constricted using a cuff to measure non-invasive blood pressure. The perfusion index value is monitored during the time of cuff pressure and cuff release. The measurement is followed by a 4-minute pause to allow the vascular supply to stabilize, the sensors are randomly rotated, and the measurement is repeated.
Study: NCT06636149

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Circuit of maternal position changes during labor
Description: The intervention cohort will undergo the circuit of position changes every 2 hours. The circuit will be repeated up to 3 times or until the second stage of labor is achieved, delivery occurs, or labor arrest diagnosis is made. Participants will be considered as adherent to intervention arm if they undergo one complete circuit of maneuvers. Nurses will keep patients on continuous fetal monitoring during the circuit of position changes. Any persistent non-reassuring fetal status in one position of the circuit will prompt progression to the next position in the circuit. The planned circuit of maneuvers will be:~10-minutes of side-lying release on one side 10-minutes of side-lying release on other side 10-minutes of open-knee chest 10-minutes of shaking apples 20-minutes of flying cowgirl on one side 20-minutes of flying cowgirl on opposite side as position 5 20-minutes of running man on same side as position 5 20-minutes of running man on opposite side as position 5
Study: NCT06636045

Intervention type: OTHER
Intervention: Not applicable- observational study
Description: No intervention. Observational study.

Intervention type: OTHER
Intervention: Not applicable- observational study
Description: No intervention. Observational study.
Study: NCT06181656

Intervention type: BIOLOGICAL
Intervention: Pneumonia vaccine
Description: Given by SC

Intervention type: BIOLOGICAL
Intervention: Pneumonia vaccine
Description: Given by SC

Intervention type: BIOLOGICAL
Intervention: Pneumonia vaccine
Description: Given by SC
Study: NCT05342064

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: patient-centered TB preventive therapy
Description: The intervention phase includes i) enrolling participants who have had TB disease excluded and allowing participant selection of a preferred TPT regimen, and ii) randomizing participants to one of two participant adherence support modalities.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TB preventive therapy adherence support
Description: As part of this study, enhanced adherence support will be provided via bi-directional messaging and/or via clinic phone calls. All participants randomized to enhanced adherence support will receive a weekly text reminder beginning seven days after the initiation. Each message will ask participants if they would like to be contacted to discuss any questions and will prompt participants to ask questions by text if more convenient or preferable. All text-based questions from participants will be answered by a trained nurse with back up from a physician.
Study: NCT06106828

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Satralizumab
Description: Satralizumab will be administered by SC injection.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered by SC injection
Study: NCT05634369

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GEM/DOX + TGFBi expanded NK cells
Description: 8 cycles consisting of gemcitabine, docetaxel, supportive dexamethasone and pegfilagrastim, and universal donor, TGFBi ex vivo expanded NK cells~* Each cycle will be repeated every 21 days based upon disease response and toxicity criteria~* Tumor response assessed after Cycles 2, 4, 6, and 8~  1. Gemcitabine 675mg/m2/dose IV on Days 1 and 8~ 2. Docetaxel 75mg/m2/dose IV on Day 8~ 3. Dexamethasone 3mg/m2/dose (max 8 mg/dose) PO BID on Days 7, 8, and 9~ 4. Pegfilgrastim (Peg-GCSF) 0.1mg/kg/dose (max 6 mg/dose) SQ on Day 9~ 5. NK cells 1 x 10e8 cells/kg/dose IV on Day 12 (+ 1-2 days)
Study: NCT06357013

Intervention type: PROCEDURE
Intervention: Bilateral Suprainguinal fascia iliaca compartment block
Description: Suprainguinal fascia iliaca compartment block (S-FICB) is one of the commonly used regional analgesia techniques for postoperative analgesia in lower extremity surgeries.

Intervention type: PROCEDURE
Intervention: Local infiltration analgesia
Description: Local infiltration analgesia is applied to the posterior part of the knee, including the periosteum, ligaments, muscle and/or skin area before closing the surgical field.
Study: NCT06471361

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zilucoplan
Description: Zilucoplan will be self-administered subcutaneously by study participants at pre-specified time points.
Study: NCT05839080

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Gardens to Bellis
Description: In FoodACT the school garden intervention that will be investigated is the well described and well-developed intervention called Gardens to Bellis. It involves pupils from 4th-5th grade and their teachers. The classes attend 8 school garden sessions distributed across two school years. The sessions start each year in March and ends in November. Pupils are divided into smaller groups, who gets a plot of which they are responsible for preparing, weed and harvest. The purpose is that pupils can cook their own food with the greens, fruits and berries they harvest in the garden and finds in the nature. The pupils and their families will hatch and harvest the school gardens between the session days.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: No intervention
Description: Pupils are not receiving any intervention
Study: NCT04802733

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MSK-DA01
Description: MSK-DA01 is an experimental product derived from human embryonic stem cells. The stem cells were converted into brain cells that produce dopamine.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MSK-DA01 Cell Delivery Device
Description: A device that is used for injection of fluids into the brain will be used. Some minor modifications have been made to the device to allow delivery of MSK-DA01 cells.
Study: NCT05467553

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid
Description: Ursodeoxycholic Acid 15 mg/kg PO QD for 60 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropeginterferon alfa-2b
Description: P1101 450 µg SC Q2W add-on at treatment week 12 for 48 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropeginterferon alfa-2b
Description: P1101 450 µg SC Q2W add-on at treatment week 12 for 48 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir Alafenamide
Description: TAF 25 mg PO QD for 60 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tenofovir Alafenamide
Description: TAF 25 mg PO QD for 60 weeks
Study: NCT04902469

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pleasant Odor
Description: Each participant in the pleasant odor condition will sniff an odor that they rated as the most intense out of a sample of odors rated to be pleasant. If this odor is the same as their self-reported preferred e-cigarette flavor, we will choose the next most intense odor out of the odors rated to be pleasant. Odors are generic and commercially available in supermarkets such as vanilla, coconut, and chocolate. Importantly, the investigators are not testing the specific odors, rather the participant's idiosyncratic response to a menu of odors. In other words, the key is that each participant in the experimental condition receives the odor that they like the best, regardless of which one it is.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Odor Blank
Description: Each participant in the odor blank condition will sniff a neutral olfactory cue (odor blank). This involves a container with no added scent. This serves as the control condition.
Study: NCT06304233

Intervention type: DIAGNOSTIC_TEST
Intervention: Echocardiography
Description: ultrasound assessment of heart structure, volume and function

Intervention type: DIAGNOSTIC_TEST
Intervention: Echocardiography
Description: ultrasound assessment of heart structure, volume and function

Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiac Magnetic Resonance Imaging
Description: MRI assessment of heart structure, volume, function and tissue characteristics

Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiac Magnetic Resonance Imaging
Description: MRI assessment of heart structure, volume, function and tissue characteristics

Intervention type: DIAGNOSTIC_TEST
Intervention: Electrocardiography
Description: Assessment of cardiac rhythm and electrical activity

Intervention type: DIAGNOSTIC_TEST
Intervention: Electrocardiography
Description: Assessment of cardiac rhythm and electrical activity

Intervention type: OTHER
Intervention: Blood sampling
Description: To measure DISC1 mRNA expression and other potential biomarkers

Intervention type: OTHER
Intervention: Blood sampling
Description: To measure DISC1 mRNA expression and other potential biomarkers
Study: NCT05834504

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Short distributed training (1-2 days)
Description: The intervention group will practice four basic skills and one procedural module on the Laparoscopic Lapsim Virtual Reality Simulator. They will practice with 1-2 days of break in between training sessions until proficiency level is achieved.
Study: NCT05525533

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Harnessing prosocial and social image motivations for behavior change
Description: The investigators will collect AGYW customer feedback using a short USSD-based survey and randomize whether shopkeepers receive 1) No feedback; 2) Private feedback; or 3) Public feedback

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Harnessing prosocial and social image motivations for behavior change
Description: The investigators will collect AGYW customer feedback using a short USSD-based survey and randomize whether shopkeepers receive 1) No feedback; 2) Private feedback; or 3) Public feedback

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Harnessing prosocial and social image motivations for behavior change
Description: The investigators will collect AGYW customer feedback using a short USSD-based survey and randomize whether shopkeepers receive 1) No feedback; 2) Private feedback; or 3) Public feedback
Study: NCT04973254

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CAB-RPV LA
Description: Monthly administration of injectable HIV medication

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CAB-RPV LA
Description: Monthly administration of injectable HIV medication

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard treatment within an HIV clinic
Description: Standard of care for HIV positive patients will be provided in the HIV clinic that may include HIV medication or may include oral medications.
Study: NCT05285683

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylphenidate
Description: 0.5 mg/kg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: carbidopa-levodopa
Description: 25 mg/100 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral pill
Study: NCT06528587

Intervention type: PROCEDURE
Intervention: narrow diameter implant
Description: Rehabilitation of single edentulism in the anterior region with narrow diameter implants and computer guided surgery.
Study: NCT05118282

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Combined coping skills + asthma management
Description: This arm includes a curriculum teaching coping skills and culturally relevant asthma management skills.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Asthma Management (AM)
Description: This arm includes a curriculum teaching standard asthma management skills.
Study: NCT05992545

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mobile application 'DangDang Care' under usual care
Description: The application incorporates a behavioral activation program to provide psychological support and enhance diabetes self-management for people with type 2 diabetes experiencing depressive symptoms, alongside conventional medical therapy.~The intervention group receives the mobile application with usual care.
Study: NCT05921084

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: MIND diet intervention
Description: The MIND diet intervention, composed of the consumption of whole grains, dark green leafy vegetables, dark red/yellow vegetables, other vegetables, berries and citrus, poultry, fish and seafoods, beans and legume, nuts, olive and seed oils, and green tea, and restricting red and processed meats, animal fat, fried foods, and sweets and pastries.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: General dietary advice
Description: General dietary advice
Study: NCT05122585

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MagSeed and MagTrace in breast cancer patiënts
Description: Combining MagSeed and Magtracer to perform a wide local excision breast conserving surgery and sentinel node biopsy.
Study: NCT03968900

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep restriction condition
Description: On day 1, participants will complete study assessments and will be fitted with an Actiwatch and instructed to continue a fixed time in bed (8 hours duration with no more than 20 min deviation) centered on habitual sleep (e.g., 11:00 p.m. to 7:00 a.m.). Naps will not be allowed. Following the one-week baseline sleep stabilization, participants will engage in the sleep restriction condition (4 hours, TIB \[Time in Bed\]; 1:00 a.m. to 5:00 a.m.). On the day of each sleep study, participants will be admitted to University of Alabama Birmingham (UAB) Highlands Hospital sleep unit at 7:00 p.m. and do an initial CO breathe test and fill out study questionnaires and a timeline follow-back procedure Participants will monitored for smoking withdrawal. Every 2 hours, participants to fill out various questionnaires. Participants will repeat the same conditions as the first night. After a two-week washout, participants will be crossed over to the alternate sleep extension/restriction condition.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep extension condition
Description: sleep extension On day 1, participants will complete study assessments and will be fitted with an Actiwatch and instructed to continue a fixed time in bed (8 hours duration with no more than 20 min deviation) centered on habitual sleep (e.g., 11:00 p.m. to 7:00 a.m.). Naps will not be allowed. Following the one-week baseline sleep stabilization, participants will engage in the sleep extension condition (10 hours, (TIB); 10:00 p.m. to 8:00 a.m.). On the day of each sleep study, participants will be admitted to University of Alabama Birmingham Highlands Hospital sleep unit at 7:00 p.m. and do an initial CO breathe test and fill out study questionnaires and a timeline follow-back procedure Participants will monitored for smoking withdrawal. Every 2 hours, participants to fill out various questionnaires. Participants will repeat the same conditions as the first night. After a two-week washout, participants will be crossed over to the alternate sleep extension/restriction condition.
Study: NCT06132568

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VITALYST System
Description: The VITALYST System is a temporary ventricular support device indicated for use during high-risk percutaneous coronary interventions (HR-PCI) performed electively in hemodynamically stable subjects with severe coronary artery disease.
Study: NCT06439550

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Serplulimab
Description: 300mg, q3w

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: First dose 8mg/kg, maintenance 6mg/kg, q3w

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin + Tegafur
Description: oxaliplatin (130mg/m2, q3w) + Tegafur (40mg/m2, bid d1-d14, q3w).
Study: NCT06570954

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: ReACT
Description: ReACT is a novel cognitive behavioral treatment and is a PNES intervention that targets sense of control and catastrophic symptom expectations. ReACT consists of 12 sessions of therapy focused on teaching patients to regain control of their body through managing thoughts and behaviors that reinforce the PNES and return to previous activities. The PNES is explained as behaviors learned through classical and operant conditioning.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: ReACT
Description: ReACT is a novel cognitive behavioral treatment and is a PNES intervention that targets sense of control and catastrophic symptom expectations. ReACT consists of 12 sessions of therapy focused on teaching patients to regain control of their body through managing thoughts and behaviors that reinforce the PNES and return to previous activities. The PNES is explained as behaviors learned through classical and operant conditioning.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: ReACT
Description: ReACT is a novel cognitive behavioral treatment and is a PNES intervention that targets sense of control and catastrophic symptom expectations. ReACT consists of 12 sessions of therapy focused on teaching patients to regain control of their body through managing thoughts and behaviors that reinforce the PNES and return to previous activities. The PNES is explained as behaviors learned through classical and operant conditioning.
Study: NCT05741385

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caffeine
Description: Caffeine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caffeine
Description: Caffeine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caffeine
Description: Caffeine
Study: NCT05141578

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Luci Coach Assisted Intervention
Description: The Luci intervention is a personalized behaviour change program delivered via an interactive mobile platform with the online support of a coach. It targets 3 lifestyle domains: physical activity, healthy diet and cognitive engagement.~Participants in this group will be encouraged to adopt a healthy lifestyle, as a means for cognitive decline/dementia risk reduction. This will be achieved by providing educational materials, practical tips and strategies, and by assisting participants outlining goals to progressively adopt and maintain a healthier lifestyle.~Coaching sessions will be held on a weekly basis from week 1 to 12, and every 2 weeks from week 13 to 24.
Study: NCT05686278

Intervention type: DEVICE
Intervention: Bipolar i and cemented stem (Océane+ or Meije)
Description: Hip hemiarthroplasty is a surgical procedure that involves replacing half of the hip joint
Study: NCT06389279

Intervention type: OTHER
Intervention: PENG block group
Description: Ultrasound-guided PENG block is performed approximately 30 minutes before surgery in patients undergoing hip surgery in a separate regional anaesthesia room with standard anaesthesia monitoring.

Intervention type: OTHER
Intervention: FIC block group
Description: Ultrasound-guided FIC block is performed approximately 30 minutes before surgery in patients undergoing hip surgery in a separate regional anaesthesia room with standard anaesthesia monitoring.

Intervention type: OTHER
Intervention: Femoral block group
Description: Ultrasound-guided femoral block is performed approximately 30 minutes before surgery in patients undergoing hip surgery in a separate regional anaesthesia room with standard anaesthesia monitoring.

Intervention type: OTHER
Intervention: Control group
Description: No intervention
Study: NCT05741385

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Warfarin sodium
Description: Warfarin sodium

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Warfarin sodium
Description: Warfarin sodium

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Warfarin sodium
Description: Warfarin sodium

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole
Description: Omeprazole

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole
Description: Omeprazole

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole
Description: Omeprazole

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metoprolol
Description: Metoprolol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metoprolol
Description: Metoprolol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metoprolol
Description: Metoprolol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Midazolam

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Midazolam

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Midazolam
Study: NCT04848506

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aficamten (5 - 20 mg)
Description: Aficamten tablets administered orally. During titration phase, clinic visits will occur approximately every 2-6 weeks. In the maintenance phase clinic visits will occur every 24 weeks, with safety check-in occurring every 12 weeks between visits by phone or, if desirable, in the clinic.
Study: NCT05363397

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TBO-309
Description: TBO-309 is a potent, selective and ATP competitive PI3Kβ inhibitor which blocks platelet activation adhesion/aggregation and promotes platelet disaggregation, thereby specifically inhibiting thrombosis without interfering with normal haemostasis.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TBO-309
Description: TBO-309 is a potent, selective and ATP competitive PI3Kβ inhibitor which blocks platelet activation adhesion/aggregation and promotes platelet disaggregation, thereby specifically inhibiting thrombosis without interfering with normal haemostasis.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TBO-309
Description: TBO-309 is a potent, selective and ATP competitive PI3Kβ inhibitor which blocks platelet activation adhesion/aggregation and promotes platelet disaggregation, thereby specifically inhibiting thrombosis without interfering with normal haemostasis.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TBO-309
Description: TBO-309 is a potent, selective and ATP competitive PI3Kβ inhibitor which blocks platelet activation adhesion/aggregation and promotes platelet disaggregation, thereby specifically inhibiting thrombosis without interfering with normal haemostasis.